How should I manage a patient with neurosarcoidosis (brain, spinal cord, optic neuritis) and lung, liver, and kidney involvement who is already receiving infliximab, regarding infliximab dosing, steroid taper, steroid‑sparing agents, and monitoring?

Management of Neurosarcoidosis Already on Infliximab

Continue infliximab at standard dosing (typically 3-5 mg/kg every 4-8 weeks) as the cornerstone of therapy, while aggressively tapering corticosteroids to the lowest effective dose or discontinuation if possible, and adding methotrexate as a steroid-sparing agent if not already on board.

Infliximab Dosing Strategy

Your patient is appropriately on infliximab, which represents third-line therapy for neurosarcoidosis according to the 2021 ERS guidelines 1. The standard approach uses 3-5 mg/kg infusions every 4-8 weeks 2, 3. Most centers use 5 mg/kg every 4-6 weeks for neurosarcoidosis given the severity of disease 3, 4.

Critical caveat: Discontinuing infliximab after 6-12 months leads to relapse in over 50% of cases 1. In neurosarcoidosis specifically, relapse rates reach 26-56% after tapering or stopping infliximab 5, 6. Therefore:

• Plan for prolonged therapy (2-3 years minimum) before considering discontinuation 7
• Re-evaluate treatment necessity every 1-2 years 1
• If disease remains in complete remission for 2+ years, cautiously consider tapering frequency (e.g., extending intervals to every 10-12 weeks) before full discontinuation
• Monitor closely for relapse, which typically occurs in the same neuroanatomic location 3

Corticosteroid Taper

Aggressive steroid tapering is essential - this is one of the primary benefits of infliximab therapy. In neurosarcoidosis studies, 68% of patients successfully tapered or discontinued corticosteroids without relapse while on infliximab 5.

Taper algorithm:

• If clinically stable on infliximab for 3-6 months, begin tapering prednisone by 5-10 mg every 2-4 weeks
• Target dose: ≤10 mg daily or complete discontinuation 7
• If disease flares during taper, increase back to last stable dose and slow taper rate
• Never abruptly stop steroids - risk of adrenal insufficiency

Steroid-Sparing Agents

Add methotrexate if not already prescribed - this is the recommended second-line agent for neurosarcoidosis 1. The treatment hierarchy per ERS guidelines is:

1. Glucocorticoids (first-line)
2. Methotrexate (second-line for inadequate response or steroid toxicity)
3. Infliximab (third-line for continued disease despite above)

Methotrexate dosing: 10-25 mg weekly (oral or subcutaneous) with folic acid supplementation 1

Rationale for adding methotrexate even on infliximab:

• Enhances infliximab efficacy
• Reduces immunogenicity and antibody formation against infliximab 2
• Provides additional steroid-sparing effect
• Most patients in successful infliximab studies were on concurrent methotrexate 5, 6

Alternative second-line agents if methotrexate contraindicated: azathioprine or mycophenolate mofetil 1, though these showed mixed results in recent cohorts 4.

Monitoring Protocol

Clinical Monitoring

• Neurological assessment every 3 months initially, then every 6 months if stable
• Document modified Rankin Scale score for objective tracking 6
• Assess specific deficits: visual acuity, cranial nerve function, motor/sensory exam, cognitive status

Imaging Surveillance

• MRI brain/spine with gadolinium every 3-6 months during first year, then every 6-12 months if stable 3
• Look for: meningeal enhancement, parenchymal lesions, optic nerve involvement, hydrocephalus
• 82% show favorable MRI response to infliximab, with 52% achieving complete remission of active disease 3

Laboratory Monitoring

For infliximab safety 2:

• CBC with differential every 3 months (watch for cytopenias)
• Hepatic panel every 3 months (transaminitis risk)
• TB screening annually (QuantiFERON or PPD) - critical given 14 TB cases in trials, 4 fatal 2
• Consider chest X-ray annually for pulmonary involvement monitoring

For methotrexate (if added) 1:

• CBC and hepatic panel every 4-8 weeks initially, then every 3 months
• Creatinine every 3 months

For disease activity:

• Serum ACE and lysozyme (limited utility but may trend with activity)
• ESR/CRP every 3-6 months
• Consider CSF analysis if clinical deterioration (protein, glucose, cell count, ACE, flow cytometry)

Systemic Organ Monitoring

Given multi-organ involvement (lung, liver, kidney):

• Pulmonary function tests every 6-12 months (FVC is key outcome measure) 1
• Chest CT annually or if symptomatic
• Hepatic function panel every 3 months
• Renal function (creatinine, urinalysis) every 3 months
• Ophthalmology evaluation every 6-12 months for optic neuritis surveillance 8, 9

Infection Risk Management

Infections are the primary concern - 29-36% of infliximab-treated neurosarcoidosis patients develop complications, with 72% being infectious 10, 5.

Prevention strategies:

• Complete age-appropriate vaccinations (avoid live vaccines while on therapy) 2
• Annual influenza vaccine, pneumococcal vaccine, COVID-19 boosters
• Low threshold for empiric antibiotics if fever develops
• Patient education on early infection signs
• Consider prophylactic trimethoprim-sulfamethoxazole if on triple immunosuppression (steroids + methotrexate + infliximab)

Specific infections reported: pneumonia, cellulitis, abscess, opportunistic infections (histoplasmosis, coccidioidomycosis, TB) 2, 10

Treatment Response Expectations

Clinical improvement: 70-77% show improvement or remission on infliximab 10, 5, 4

• Complete neurologic recovery: 21-29%
• Partial improvement: 48-50%
• Stable disease: 18-25%

MRI improvement: 82% show favorable response 3

Time to response: Most improvement occurs within first 6 months 5, 3

Key Pitfalls to Avoid

1. Premature discontinuation of infliximab - maintain for minimum 2-3 years given high relapse rates
2. Inadequate steroid taper - prolonged high-dose steroids negate infliximab's steroid-sparing benefit
3. Missing occult infections - maintain high suspicion, especially TB reactivation
4. Inadequate immunogenicity prevention - use concurrent methotrexate to reduce antibody formation
5. Insufficient monitoring - regular MRI surveillance is essential to detect subclinical progression

This evidence-based approach balances aggressive disease control with minimization of treatment toxicity, prioritizing the mortality and morbidity risks inherent in both untreated neurosarcoidosis and immunosuppressive therapy complications.